IFNB1 and myeloid sarcoma: As such, they included patients with different types of MS (for instance, RRMS, PPMS, SPMS in the study by Sorosina et al. (2018)), or both untreated and treated with IFN-β (for instance, in the study by Santoro et al. (2017)).